ACE Inhibition and Angiotensin Receptor Blocker Treatment on Skeletal Muscle Fat Content in Aged Rats

Christy S. Carter, PhD (Department of Aging and Geriatric Research, COM, UF)

Introduction
Age-related changes in body composition (increased fat mass, decreased lean mass), muscle energy expenditure and physiology, may contribute to declining physical performance and ultimately disability. It is unclear whether these pathophysiological changes precede the development of or are a consequence of declining function and whether preventing these changes will also prevent the progression of disability. We are currently funded (NIA 1 R01 AG024526-01A1) to assess the long-term effects of an angiotensin converting enzyme (ACE) inhibitor, enalapril, and angiotensin receptor blocker (ARB), losartan, on physical performance, muscle quality and body composition in aged rats. ACEi have two well-established effects: 1) they prevent the conversion of ANGI to ANGII, and 2) they block the proteolytic degradation of bradykinin; whereas ARBs antagonize the binding of ANGII to the AT1 receptor. For example, clinical data demonstrate that the onset of diabetes begins with the development of insulin resistance in adipocytes and ultimately results in skeletal muscle and whole body insulin resistance. Long-term trials in hypertensive persons using either ARBs or ACEi have shown that both reduce the risk of developing metabolic abnormalities in fat and muscle associated with type II diabetes. Studies in hypertensives and obese rat models of these conditions show that both ACEi and ARB treatment results in weight loss and improvements in insulin sensitivity. However, there are relatively little data concerning the metabolic effects of ACEi or ARBs in normotensive aged rodents, although these animals demonstrate age-related pathophysiological changes that are very similar (e.g., insulin insensitivity and obesity related metabolic impairments). Our central hypothesis revolves around the idea that age-related “insulin resistance” contributes to the disregulation of metabolic functioning of skeletal muscle tissue and may contribute to declining performance. While the loss of muscle mass per se with aging does not seem to result in glucose intolerance, the increased fat content within skeletal muscle could play a role in the development of insulin resistance and have profound effects on muscle quality. Recent studies indicate that increased lipid content within skeletal muscle may contribute to insulin resistance in humans and rodents.

Experimental
In conjunction with the ARMIS, we have collected preliminary data on a group of aged rats who have received enalapril or losartan, or vehicle control for a period of 6 months (24 to 30 months of age). Using MR technology we should be able to develop more refined measurements of determining longitudinal changes in quality of skeletal muscle, specifically changes in fat content of skeletal muscle and relate these changes to declining performance. We propose to measure three animals per group, for a total of 9 animals, at three time points (24 months—pre drug; 27 months—when performance begins to decline in older animals; and 30 months—where a majority of animals begin to decline). We will assess fat content in soleus muscle using standard SE images w/without water suppression, followed by a localised voxel (STEAM).

Results and Discussion
Preliminary data has been collected on spectroscopy and is currently being analyzed with Dr. Glen Walter. We will publish these results shortly following the analyses.

Conclusions
This application represents a first step in describing longitudinal changes in the age-related pathophysiology of skeletal muscle and the onset of declining physical performance, as well as the role of long-term ACEi and ARB treatment in reversing these changes. In the long-term, evaluating the therapeutic effects of long-term ACE inhibition and ARB treatment on changed metabolism in adipose tissue and skeletal muscle as well as changes in body composition and physical function in rodents will influence ongoing randomized clinical trials in humans and help elucidate the biological mechanisms by which the changes occur. The results from this study will be used as preliminary data for a larger NIH funded study to assess the effects of a variety of pharmacological and behavioral interventions on declining performance and muscle quality. In fact we have received a supplement to the RO1 this grant is based on to investigate mitochondrial function and skeletal muscle glucose transport in our model. This will be enhanced by the spectroscopy. We plan to include aims that are specifically focused on imaging and that will support and enhance studies that are currently conducted at the ART.

Acknowledgements
This application was sponsored by a grant from the National Institute on Aging (NIA 1 R01 AG024526-01A1).